🔥🐔 BizChicken 🐔🔥

Companies Similar to Cartesian Therapeutics, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CAN-2409, CAN-3110

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing immunotherapies for cancer patients, with products like CAN-2409 and CAN-3110 in various clinical trial phases.

Tags: biopharmaceutical, cancer treatment, clinical trials, immunotherapies

Symbol: CADL

Recent Price: $7.95

Industry: Biotechnology

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Sector: Healthcare

Employees: 42

Address: 117 Kendrick Street, Needham, MA 02494

Phone: 617 916 5445

Last updated: 2024-12-31

Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

DNTH103

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on designing, developing, and delivering novel monoclonal antibodies for severe autoimmune and inflammatory diseases. Their lead product, DNTH103, is in phase 1 clinical trials.

Tags: autoimmune diseases, biotechnology, clinical-stage, inflammatory diseases, monoclonal antibodies

Symbol: DNTH

Recent Price: $21.50

Industry: Biotechnology

CEO: Mr. Marino Garcia M.B.A.

Sector: Healthcare

Employees: 53

Address: 7 Times Square, New York, NY 10036

Phone: 929-999-4055

Last updated: 2024-12-31

Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

ELI-002

Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for cancer and other diseases, with its lead product ELI-002 targeting KRAS-driven cancers.

Tags: Biotechnology, Cancer Treatment, Clinical-stage, Immunotherapy, Vaccines

Symbol: ELTX

Recent Price: $5.00

Industry: Biotechnology

CEO: Mr. Robert T. Connelly

Sector: Healthcare

Employees: 32

Address: 451 D Street, Boston, MA 02210

Phone: 857-209-0050

Last updated: 2024-12-31

Statera Biopharma, Inc.

Statera Biopharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

STAT-201, Entolimod, STAT-401, STAT-205

Statera Bio Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat autoimmune diseases, cancers, and infectious diseases by rebalancing the immune system.

Tags: autoimmune, biopharmaceutical, cancer, immune system, immunotherapy, infectious diseases, novel therapies

Symbol: STAB

Recent Price: $0.00

Industry: Biotechnology

CEO: Mr. Michael Kevin Handley

Sector: Healthcare

Employees: 46

Address: 2537 Research Boulevard, Fort Collins, CO 80526

Phone: 888 613 8802

Last updated: 2024-12-31

Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals, Inc. logo
Market Cap: High
Employees: Low

SNDX-5613, SNDX-6352 (axatilimab), Entinostat

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer treatment, including innovative candidates like SNDX-5613 and SNDX-6352. It collaborates with notable institutions like the National Cancer Institute and has a license agreement with Kyowa Hakko Kirin Co., Ltd.

Tags: Collaborations, Entinostat, Monoclonal Antibody, SNDX-5613, SNDX-6352, biopharmaceutical, cancer therapy, clinical-stage

Symbol: SNDX

Recent Price: $12.52

Industry: Biotechnology

CEO: Mr. Michael A. Metzger M.B.A.

Sector: Healthcare

Employees: 184

Address: 35 Gatehouse Drive, Waltham, MA 02451

Phone: 781 419 1400

Last updated: 2024-12-31

Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. logo
Market Cap: Lowest
Employees: Low

TNX-1500, TNX-2900, TNX-801, TNX-1840, TNX-1850, TNX-3500

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company that focuses on developing therapies for immunology, rare diseases, infectious diseases, and central nervous system disorders. Key products include TNX-1500 for organ transplant and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, and TNX-801 for smallpox prevention.

Tags: CNS, autoimmunity, biopharmaceutical, cancer, immunology, infectious disease, rare disease, therapeutics

Symbol: TNXP

Recent Price: $0.36

Industry: Biotechnology

CEO: Dr. Seth Lederman M.D.

Sector: Healthcare

Employees: 103

Address: 26 Main Street, Chatham, NJ 07928

Phone: 862 799 8599

Last updated: 2024-12-31

Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

Zunsemetinib

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immune-inflammatory diseases. It operates through Therapeutics and Contract Research segments, addressing unmet needs with innovative therapies, including treatments for rheumatoid and psoriatic arthritis, atopic dermatitis, autoimmune diseases, inflammatory bowel disease, and certain cancers.

Tags: atopic dermatitis, autoimmune diseases, biopharmaceutical, cancer, contract research, drug development, immune-inflammatory diseases, psoriatic arthritis, rheumatoid arthritis, therapeutics

Symbol: ACRS

Recent Price: $2.48

Industry: Medical - Diagnostics & Research

CEO: Dr. Neal S. Walker D.O., M.D.

Sector: Healthcare

Employees: 86

Address: 640 Lee Road, Wayne, PA 19087

Phone: 484 324 7933

Last updated: 2024-12-31

Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

T-cell immunotherapy treatments

Atara Biotherapeutics, Inc. is a company focused on developing off-the-shelf T-cell immunotherapy treatments for patients with cancer, autoimmune, and viral diseases, including tabelecleucel for EBV driven diseases, next-generation CAR T therapies, and the ATA368 program for HPV associated cancers.

Tags: Autoimmune Diseases, Biotherapeutics, Cancer Treatment, Immunotherapy, T-Cell Therapy, Viral Diseases

Symbol: ATRA

Recent Price: $13.28

Industry: Biotechnology

CEO: Dr. Anhco Nguyen Ph.D.

Sector: Healthcare

Employees: 165

Address: 611 Gateway Boulevard, South San Francisco, CA 94080

Phone: 650 278 8930

Last updated: 2024-12-31

Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. logo
Market Cap: Low
Employees: Lowest

CLR 131

Cellectar Biosciences, Inc. is a clinical biopharmaceutical company concentrating on the development and commercialization of drugs for cancer treatment.

Tags: biopharmaceutical, cancer treatment, drug development, phospholipid drug conjugate

Symbol: CLRB

Recent Price: $0.29

Industry: Biotechnology

CEO: Mr. James V. Caruso

Sector: Healthcare

Employees: 20

Address: 100 Campus Drive, Florham Park, NJ 07932

Phone: 608 441 8120

Leadership

  • James Caruso, President, CEO and Director
  • Chad Kolean, Chief Financial Officer
  • Shane Lea, Chief Commercial Officer
  • Jarrod Longcor, Chief Operating Officer
  • Andrei Shustov, Senior Vice President, Medical
  • Douglas J. Swirsky, Chairman of the Board
  • Asher Alban Chanan-Khan, MD., Director
  • Frederick W. Driscoll, Director
  • Stefan D. Loren, Ph.D., Director
  • John Neis, Director
  • Cellectar Biosciences, Inc., Company Information

Last updated: 2024-12-31

Compass Therapeutics, Inc.

Compass Therapeutics, Inc. logo
Market Cap: Low
Employees: Lowest

CTX-009, CTX-471, CTX-8371

Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing antibody-based therapeutics to treat various human diseases. Their clinical stage products include investigational bispecific antibodies like CTX-009 and monoclonal antibodies such as CTX-471.

Tags: CTX-009, CTX-471, CTX-8371, antibody therapeutics, biopharmaceutical, clinical stage, oncology

Symbol: CMPX

Recent Price: $1.48

Industry: Biotechnology

CEO: Dr. Thomas J. Schuetz M.D., Ph.D.

Sector: Healthcare

Employees: 32

Address: 80 Guest Street, Boston, MA 02135

Phone: 617 500 8099

Last updated: 2024-12-31

Caribou Biosciences, Inc.

Caribou Biosciences, Inc. logo
Market Cap: Low
Employees: Low

CB-010, CB-011, CB-012, CB-020

Caribou Biosciences is a clinical-stage biopharmaceutical company focused on developing genome-edited allogeneic cell therapies for treating hematologic malignancies and solid tumors, with several product candidates in clinical trials.

Tags: CAR-NK, CAR-T, biopharmaceutical, cell therapies, clinical-stage, genome-edited therapies, hematologic malignancies, solid tumors

Symbol: CRBU

Recent Price: $1.61

Industry: Biotechnology

CEO: Dr. Rachel E. Haurwitz Ph.D.

Sector: Healthcare

Employees: 158

Address: 2929 7th Street, Berkeley, CA 94710

Phone: 510 982 6030

Last updated: 2024-12-31

Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

Decoy20

Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company focusing on the development of anti-cancer and anti-viral immunotherapy products, with its lead clinical candidate, Decoy20, targeting lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as viral infections.

Tags: Decoy20, anti-cancer, anti-viral, biotechnology, immunotherapy

Symbol: INDP

Recent Price: $0.87

Industry: Biotechnology

CEO: Mr. Jeffrey A. Meckler

Sector: Healthcare

Employees: 7

Address: 3 Columbus Circle, New York, NY 10019

Phone: 347 480 9760

Last updated: 2024-12-31

Nkarta, Inc.

Nkarta, Inc. logo
Market Cap: Low
Employees: Low

NKX101 and NKX019

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing cell therapies for the treatment of cancer. The company specializes in cellular immunotherapy using chimeric antigen receptors on natural killer cells to target tumor antigens.

Tags: NK cells, biopharmaceutical, cancer treatment, cell therapy, clinical trials, immunotherapy

Symbol: NKTX

Recent Price: $2.32

Industry: Biotechnology

CEO: Mr. Paul J. Hastings

Sector: Healthcare

Employees: 150

Address: 6000 Shoreline Court, South San Francisco, CA 94080

Phone: 415 582 4923

Last updated: 2024-12-31

Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. logo
Market Cap: High
Employees: Low

NX-2127, NX-5948, NX-1607, NX-0255

Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.

Tags: BTK degrader, CBL-B inhibitor, biopharmaceutical, cancer, clinical trials, immune disorders

Symbol: NRIX

Recent Price: $18.64

Industry: Biotechnology

CEO: Dr. Arthur T. Sands M.D., Ph.D.

Sector: Healthcare

Employees: 284

Address: 1700 Owens Street, San Francisco, CA 94158

Phone: 415 660 5320

Last updated: 2024-12-31

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. logo
Market Cap: High
Employees: Medium

NTLA-2001, NTLA-2002, NTLA-5001

Intellia Therapeutics, Inc. is a genome editing company specializing in developing therapeutics, with a focus on in vivo and ex vivo programs, including treatments for transthyretin amyloidosis, hereditary angioedema, and acute myeloid leukemia. The company also develops engineered cell therapies and offers CRISPR/Cas9 tools.

Tags: CRISPR, autoimmune disorders, ex vivo, genome editing, in vivo, oncology, therapeutics

Symbol: NTLA

Recent Price: $11.41

Industry: Biotechnology

CEO: Dr. John M. Leonard M.D.

Sector: Healthcare

Employees: 526

Address: 40 Erie Street, Cambridge, MA 02139

Phone: 857 285 6200

Last updated: 2024-12-31

Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. logo
Market Cap: Lowest
Employees: Lowest

INTASYL therapeutic platform

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics using its INTASYL therapeutic platform to target tumor and immune cells by regulating genes of the immune system, focusing on products like PH-762, PH-894, and PH-804 for enhancing cancer immunotherapies in adoptive cell transfer.

Tags: ACT, BRD4, Biotechnology, Cancer, Immuno-Oncology, PD-1, TIGIT, Therapeutics

Symbol: PHIO

Recent Price: $1.90

Industry: Biotechnology

CEO: Mr. Robert J. Bitterman

Sector: Healthcare

Employees: 8

Address: 257 Simarano Drive, Marlborough, MA 01752

Phone: 508 767 3861

Last updated: 2024-12-31

Cartesian Therapeutics, Inc.

Cartesian Therapeutics, Inc. logo
Market Cap: Medium
Employees: Lowest

SEL-302, SEL-212

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing nanoparticle immunomodulatory drugs for treating and preventing human diseases. The company has various programs including gene therapies and biologic therapies for conditions like methylmalonic acidemia and chronic refractory gout.

Tags: autoimmune diseases, biologic therapies, biopharmaceutical, gene therapy, nanoparticle drugs

Symbol: RNAC

Recent Price: $18.76

Industry: Biotechnology

CEO: Dr. Carsten Brunn Ph.D.

Sector: Healthcare

Employees: 37

Address: 65 Grove Street, Watertown, MA 02472

Phone: 617 923 1400

Last updated: 2024-12-31

Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. logo
Market Cap: Lowest
Employees: Lowest

XCART

Xenetic Biosciences, Inc. is a biopharmaceutical company that focuses on advancing XCART, a personalized CAR T platform technology for oncology therapeutics and biologic drug development.

Tags: CAR T, biopharmaceutical, biotechnology, drug delivery, oncology, therapeutics

Symbol: XBIO

Recent Price: $4.05

Industry: Biotechnology

CEO: Mr. James F. Parslow

Sector: Healthcare

Employees: 4

Address: 40 Speen Street, Framingham, MA 01701

Phone: 781 778 7720

Leadership

  • James F. Parslow, Interim Chief Executive Officer and Chief Financial Officer
  • Scott N. Cullison, Business Development
  • Reid P. Bissonnette, Ph.D., Translational Research and Development
  • Cory C. Kauffman, Ph.D., Chief Technology Officer
  • Adam Logal, Chairman
  • Grigory G. Borisenko, Ph.D., Non-Executive Director
  • James Eric Callaway, Ph.D., Non-Executive Director
  • Firdaus Jal Dastoor, FCS, Non-Executive Director
  • Dmitry Genkin, MD, Non-Executive Director
  • Roger Kornberg, Ph.D., Non-Executive Director
  • Moshe Mizrahy, Non-Executive Director
  • Dr. Alexey Vinogradov, Non-Executive Director

Last updated: 2024-12-31

Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Low

XTX101

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients with a focus on tumor-selective therapies.

Tags: biotechnology, cancer treatment, checkpoint inhibitors, clinical-stage, immunotherapies

Symbol: XLO

Recent Price: $0.97

Industry: Biotechnology

CEO: Dr. Rene Russo BCPS, Pharm.D.

Sector: Healthcare

Employees: 73

Address: 828 Winter Street, Waltham, MA 02451

Phone: 617 430 4680

Last updated: 2024-12-31

Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. logo
Market Cap: Lowest
Employees: Lowest

SLS-002, SLS-005, SLS-006, SLS-007, SLS-008, SLS-004, SLS-010

Seelos Therapeutics, Inc. is focused on developing and commercializing therapeutics for central nervous system, respiratory, and other disorders, with lead programs targeting major depressive disorders, amyotrophic lateral sclerosis, Sanfilippo syndrome, and Parkinson's disease.

Tags: ALS, Parkinson's disease, Sanfilippo syndrome, biopharmaceutical, central nervous system, major depressive disorder, respiratory disorders, therapeutics

Symbol: SEEL

Recent Price: $0.37

Industry: Biotechnology

CEO: Dr. Raj Mehra J.D., Ph.D.

Sector: Healthcare

Employees: 8

Address: 300 Park Avenue, New York, NY 10022

Phone: 646 293 2100

Last updated: 2024-12-31